Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
pp65 is the principal tegument protein of HCMV, constituting a significant portion of the virion mass[3]. Its key roles are as a structural scaffolding protein and as a "modulator" of the host immune response. It directly inhibits host antiviral signaling by blocking IRF-3 nuclear accumulation and interferon signaling[2][6], reduces NF-κB DNA-binding in infected cells, and interacts with NK cell receptors to suppress cytotoxicity[1][6]. pp65 is dispensable for viral replication in fibroblasts but is important for efficient replication in monocyte-derived macrophages[1]. As one of the most immunogenic HCMV antigens, pp65 is central to both cellular and humoral immune responses, and its presence is widely used for diagnosing and monitoring active HCMV infection in clinical practice via antigenemia assays and T cell response tests[2][4]. It is also under investigation as a target for HCMV vaccine development and adoptive T cell therapies[2][4][5].
For therapies and monitoring: induction of protective T cell responses, antibody generation, monitoring via pp65 antigenemia assays in transplantation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major tegument protein of Human cytomegalovirus (pp65) (pp65 (also known as UL83)).